

iCo Therapeutics Inc.
(a development stage company)

Financial Statements
December 31, 2009 and 2008

April 27, 2010

Auditors' Report

To the Shareholders of iCo Therapeutics Inc.

We have audited the balance sheets of **iCo Therapeutics Inc.** (a development stage company) as at December 31, 2009 and 2008 and the statements of operations, comprehensive loss and deficit and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

In our opinion, these financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2009 and 2008 and the results of its operations and its cash flows for the years then ended in accordance with Canadian generally accepted accounting principles.

(signed) PricewaterhouseCoopers LLP

Chartered Accountants

iCo Therapeutics Inc.

(a development stage company)

Balance Sheets

As at December 31, 2009 and 2008

	2009 \$	2008 \$
Assets		
Current assets		
Cash and cash equivalents	1,384,802	620,276
Short-term investments	2,511,263	-
Taxes and other receivable	34,933	42,950
Prepaid expenses	22,499	13,770
	<hr/>	<hr/>
	3,953,497	676,996
Equipment (note 4)	16,514	23,830
Intangible assets (note 5)	658,539	765,005
	<hr/>	<hr/>
	4,628,550	1,465,831
	<hr/>	<hr/>
Liabilities		
Current liabilities		
Accounts payable and accrued liabilities	322,778	442,800
	<hr/>	<hr/>
Shareholders' Equity (note 6)		
Capital stock	15,733,967	10,666,921
Contributed surplus	1,599,669	1,410,612
Warrants	335,128	-
Deficit	(13,362,992)	(11,054,502)
	<hr/>	<hr/>
	4,305,772	1,023,031
	<hr/>	<hr/>
	4,628,550	1,465,831
	<hr/>	<hr/>

Nature of operations and going concern (note 1)

Commitments and contingencies (note 12)

Subsequent events (note 15)

Approved by the Board of Directors

_____ (signed) William Jarosz _____ Director

_____ (signed) Andrew Rae _____ Director

iCo Therapeutics Inc.

(a development stage company)

Statements of Operations, Comprehensive Loss and Deficit

	Year ended December 31, 2009 \$	Year ended December 31, 2008 \$	Cumulative from inception to December 31 2009 \$
Interest income	6,354	30,529	105,951
Expenses			
Research and development (note 10)	1,133,696	1,421,258	8,246,003
General and administrative (note 11)	836,947	995,297	3,600,646
Amortization	116,845	115,430	440,194
Foreign exchange loss	37,710	60,950	180,457
Stock-based compensation	189,646	179,968	826,229
Transaction costs	-	-	175,414
	<u>2,314,844</u>	<u>2,772,903</u>	<u>13,468,943</u>
Loss and comprehensive loss for the year	(2,308,490)	(2,742,374)	(13,362,992)
Deficit accumulated during the development stage - Beginning of year	<u>(11,054,502)</u>	<u>(8,312,128)</u>	-
Deficit accumulated during the development stage - End of year	<u>(13,362,992)</u>	<u>(11,054,502)</u>	<u>(13,362,992)</u>
Basic and diluted loss per share	<u>(0.08)</u>	<u>(0.14)</u>	
Weighted average number of shares	<u>29,542,334</u>	<u>20,077,165</u>	

iCo Therapeutics Inc.

(a development stage company)

Statements of Cash Flows

	Year ended December 31, 2009 \$	Year ended December 31, 2008 \$	Cumulative from inception to December 31, 2009 \$
Cash flows from operating activities			
Loss for the year	(2,308,490)	(2,742,374)	(13,362,992)
Items not affecting cash			
Amortization	116,845	115,430	440,194
Stock-based compensation	189,646	179,968	826,229
Foreign exchange gain on conversion of note payable	-	-	(2,580)
Shares issued for service (note 5(a))	-	-	1,311,625
	(2,001,999)	(2,446,976)	(10,787,524)
Changes in non-cash working capital			
Taxes and other receivable	8,017	192,570	(1,860)
Tax credits receivable	-	209,000	(33,073)
Prepaid expenses	(8,729)	3,165	(22,499)
Accounts payable and accrued liabilities	(120,022)	(341,141)	31,454
	(2,122,733)	(2,383,382)	(10,813,502)
Cash flows from investing activities			
Purchase of equipment	(3,065)	(18,071)	(51,242)
Purchase of short term investments	(2,511,263)	42,174	(2,511,263)
Purchase of intangible assets	-	-	(481,931)
Deposits	-	-	407,050
	(2,514,328)	24,103	(2,637,386)
Cash flows from financing activities			
Exercise of warrants	158,250	4,276	201,775
Exercise of options	5,500	3,750	9,250
Issuance of units	5,767,500	1,140,450	15,767,302
Unit issuance costs	(529,663)	(58,154)	(1,142,637)
	5,401,587	1,090,322	14,835,690
Increase (decrease) in cash and cash equivalents	764,526	(1,268,957)	1,384,802
Cash and cash equivalents - Beginning of year	620,276	1,889,233	-
Cash and cash equivalents - End of year	1,384,802	620,276	1,384,802
Supplementary information			
Cash received for interest	6,354	30,529	

iCo Therapeutics Inc.

(a development stage company)

Notes to Financial Statements

December 31, 2009 and 2008

1 Nature of operations and going concern

Nature of operations

iCo Therapeutics Inc. (“iCo” or the “Company”) is a development stage pharmaceutical company focused on the reprofiling and repositioning of drugs and drug candidates with a previous clinical history for new disease indications. iCo’s current business strategy is to acquire the rights to drugs and drug candidates from third parties and run human clinical trial programs for new disease indications, with an emphasis on ophthalmology. The Company currently has three compounds under development. The first, iCo-007, is an anti-sense molecule currently in a Phase I clinical trial for diabetic macular edema. iCo-008 is a monoclonal antibody that the Company plans to take into a Phase II clinical trial for allergic conjunctivitis. iCo-009 is an experimental oral formulation of Amphotericin B that is at a pre-clinical stage. The Company is considered to be in the development stage as most of its efforts have been devoted to research and development, raising capital, recruitment of personnel and long-term planning. The Company is publicly traded on the TSX Venture Exchange under the symbol “ICO”.

On January 1, 2009, the Company amalgamated with its wholly owned subsidiary, iCology Corporation. iCology Corporation was a dormant holding company and the amalgamation was for the purposes of simplifying the Company’s corporate structure and reducing accounting and administrative overhead.

Going concern

These financial statements have been prepared using Canadian generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they come due. The recoverability of the Company’s intangible and other long-term assets and its ability to continue as a going concern is dependent upon its ability to fund its research and development programs, manage its foreign currency exposures, defend its patent rights and generate positive cash flows from operations.

For the year ended December 31, 2009, the Company reported a loss of \$2,308,490 and an accumulated deficit of \$13,362,992 at that date. Subsequent to December 31, 2009, the Company received cash proceeds of \$810,563 from the exercise of 2,701,875 warrants (refer to note 15). As at December 31, 2009, the Company had cash and short-term investments on hand of \$3,896,065 and working capital of \$3,630,719. However, as the Company does not have the prospect of achieving revenues in the near future, the Company will require additional funding to maintain its research and development projects and for general operations. These circumstances lend significant doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern.

Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. Management plans to secure the necessary financing through the issue of new equity and/or the entering into of strategic partnership arrangements. Nevertheless, there is no assurance that these initiatives will be successful.

iCo Therapeutics Inc.

(a development stage company)

Notes to Financial Statements

December 31, 2009 and 2008

These financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and balance sheet classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material.

2 Significant accounting policies

Generally accepted accounting principles

These financial statements have been prepared in accordance with accounting principles generally accepted in Canada and are presented in Canadian dollars.

Development stage company

The accompanying financial statements have been prepared in accordance with the provisions of Accounting Guideline No. 11, *Enterprises in the Development Stage* (note 1).

Use of estimates

The preparation of financial statements in conformity with Canadian generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the period. While management believes that these estimates and assumptions are reasonable, actual results could vary significantly. Significant areas requiring the use of estimates and assumptions include the determination of future income taxes, the recoverability of intangible and other long-term assets and the calculation of fair value for stock-based compensation transactions.

Cash and cash equivalents

Cash and cash equivalents consist of cash on deposit and highly liquid short-term interest-bearing securities with maturities at the date of purchase of three months or less. Cash and cash equivalents are held at recognized Canadian financial institutions. Interest earned is recognized in the consolidated statements of operations.

Short-term investments

The Company’s investments, which consist of money market accounts and banker’s acceptances, are classified as held to maturity for accounting purposes and carried on the consolidated balance sheets at amortized cost using the effective interest method, plus accrued interest. Investments with maturities of greater than 90 days and less than one year are classified as short-term investments.

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

Government assistance and investment tax credits

The Company periodically applies for financial assistance under available government incentive programs. The Company recognizes government assistance and investment tax credits for qualifying research and development costs when the Company has complied with the terms and conditions of the approved grant program or applicable tax legislation and there is reasonable assurance the government assistance or investment tax credit will be realized.

Government assistance related to research grants for operating expenses is recorded as a reduction of related expenses in the period when the receipt of such assistance is reasonably assured. Government assistance relating to refundable investment tax credits resulting from research and development expenditures is recorded as a reduction of related expenses.

When the Company completed its reverse takeover (“RTO”) in December 2007, the Company was no longer eligible for new investment tax credits. Investment tax credits recorded in 2008 relate to the balance of the 2007 claim. In 2009, the Company had no investment tax credits.

Equipment

Equipment is recorded at cost less accumulated amortization. Management reviews equipment for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability is assessed by management by comparing the carrying amount to the estimated future net cash flows the assets are expected to generate. Where the carrying value exceeds estimated future net cash flows, the assets are written down to fair value.

Amortization is provided based on the estimated useful lives of the equipment using the straight-line method at the following annual rates:

Computer equipment	3 years
Computer software	2 years
Office equipment	5 years

Intangible assets

Intangible assets include licenses. Expenditures incurred to prepare, file and obtain licenses are recorded at cost less accumulated amortization. Amortization is provided on a straight-line basis over the terms of the related licenses, which range from 10 to 15 years.

Intangible assets are reviewed for impairment upon the occurrence of events or changes in circumstances indicating that the carrying value of the asset may not be recoverable, as measured by comparing their net book value to the estimated undiscounted future cash flows generated by their use. Impaired assets are recorded at fair value, determined using discounted future cash flows expected from their use and eventual disposition.

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

Share issue costs

Direct costs associated with an issue of capital stock or warrants are deducted from the related proceeds at the time of the issuance.

Stock-based compensation

The Company grants stock options to directors, officers, employees and consultants pursuant to a stock-based compensation plan described in note 6. Compensation expense is recorded for stock options issued to employees and non-employees using the fair value method with a corresponding increase in contributed surplus. Any consideration received on exercise of stock options or the purchase of stock, plus the fair value of options or stock, is credited to capital stock.

Under the fair value method, stock-based payments to non-employees are measured at the fair value of the equity instrument issued. The fair value of stock-based payments to non-employees is periodically re-measured until the earlier of completion of the services provided, a firm commitment to complete the services, or the vesting date; any change in fair value is recognized over the service period.

Research and development

Research expenditures are expensed in the period incurred. Product development expenditures are expensed as incurred unless the product candidate meets criteria for deferral and amortization under Canadian GAAP. No product development expenditures have been deferred to date.

Foreign currency transactions

Monetary assets and liabilities denominated in currencies other than the Canadian dollar are translated at the rate of exchange in effect at the end of the period. Revenue and expense items are translated at the rate of exchange in effect on the dates they occur. Exchange gains or losses are recognized immediately in the consolidated statements of operations.

Future income taxes

The Company follows the liability method of accounting for income taxes. Under this method, current income taxes are recognized for the estimated income taxes payable for the current period. Future income tax assets and liabilities are recognized in the current period for temporary differences between the tax and accounting basis of assets and liabilities as well as for the benefit of losses available to be carried forward to future years for tax purposes. Future income tax assets and liabilities are measured using substantively enacted tax rates and laws expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on future income tax assets and liabilities is recognized in operations in the period that includes the substantive enactment.

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

Comprehensive income

The Company adopted the recommendations of Canadian Institute of Chartered Accountants (“CICA”) Handbook Section 1530, *Comprehensive Income*. This section establishes standards for reporting and presenting comprehensive income, which is defined as the change in equity from transactions and other events from non-owner sources. Other comprehensive income refers to items recognized in comprehensive income that are excluded from net income calculated in accordance with GAAP. The Company’s comprehensive loss is equal to its net loss.

Basic and diluted loss per common share

Loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding. As at December 31, 2009, all 2,521,429 (2008 - 1,766,072) options were excluded from the calculation of diluted shares as their exercise price was below the prevailing market price and accordingly, the effects of the calculation were anti-dilutive.

Financial instruments

Recognition and measurement

The Company adopted CICA Handbook Section 3855, *Financial Instruments - Recognition and Measurement*; Section 3861, *Financial Instruments - Disclosure and Presentation*; and Section 3251, *Equity*, on a retroactive basis, without restatement of prior periods. Among other things, these sections specify when a financial instrument or non-financial derivative is to be recognized on the balance sheets, require a financial instrument derivative to be measured at fair value or using cost-based measures, depending on its classification, and establish how gains or losses are to be recognized and presented.

The Company has made the following classifications for its financial instruments:

- a) Cash and cash equivalents are classified as assets held-for-trading and are measured at fair value at the end of each period, with any resulting gains or losses recognized as net gains or losses in the consolidated statements of operations.
- b) Accounts receivable are initially measured at fair value and subsequently at amortized cost using the effective interest rate method, less provisions for impairment.
- c) Short-term investments are classified as held to maturity and are measured at fair value upon initial measurement and subsequently at amortized cost using the effective interest rate method.
- d) Accounts payable are initially measured at fair value and subsequently at amortized cost using the effective interest rate method.

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

Disclosure and presentation

On January 1, 2008, the Company adopted the CICA Handbook Section 3862, *Financial Instruments - Disclosures*, and Section 3863, *Financial Instruments - Presentation*. Section 3862 describes the required disclosure to evaluate the significance of financial instruments for the entity's financial position and performance as well as the nature and extent of risks arising from financial instruments to which the entity is exposed and how the entity manages those risks. See note 13.

Section 3863 establishes standards for presentation of financial instruments and non-financial derivatives. It details the presentation of standards described in Section 3861, *Financial Instruments - Disclosure and Presentation*.

Capital disclosures

On January 1, 2008, the Company adopted CICA Handbook Section 1535, *Capital Disclosures*. The new standard requires disclosure of quantitative information that enables users of financial statements to evaluate the Company's objectives, policies and processes for managing capital. See note 14.

Changes in accounting policy

Credit Risk and the Fair Value of Financial Assets and Financial Liabilities

In January 2009, the Company adopted the recommendation of the Emerging Issues Committee No. 173, *Credit Risk and the Fair Value of Financial Assets and Financial Liabilities*, issued by the CICA. This abstract clarifies that an entity's own credit risk and the credit risk of its counterparty should be taken into consideration in determining the fair value of financial assets and liabilities. The adoption of this section did not have a material impact on the Company's financial statements.

Financial Instruments - Disclosures

In June 2009, the Company adopted the amendments to Section 3862, *Financial Instruments - Disclosures*, issued by the CICA. The amendments improved disclosures about fair value measurements of financial instruments, including the relative reliability of the inputs used to those measurements and liquidity risk, in light of concerns that the nature and extent of liquidity risk requirements were unclear and difficult to apply. The amendments to Section 3862 apply to annual financial statements relating to fiscal years ending after September 30, 2009. The adoption of this section did not have any measurement impact on the Company's financial statements. The additional disclosure requirements are presented in note 13.

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

Goodwill and intangible assets

In February 2008, the CICA issued Handbook Section 3064, *Goodwill and Intangible Assets*, which replaces Handbook Section 3062, *Goodwill and Other Intangible Assets*, and Section 3450, *Research and Development Costs*. This revision aligns Canadian GAAP with International Financial Reporting Standards (“IFRS”) and establishes standards for the recognition, measurement, presentation and disclosure of goodwill and intangible assets. This section applies to fiscal years beginning October 1, 2008.

The adoption of this standard, effective for the Company on January 1, 2009, did not impact the Company’s operating results or financial position.

New accounting pronouncements

Business combinations, consolidated financial statements and non-controlling interests

In January 2008, the CICA introduced Handbook Section 1582 to replace Handbook Section 1581, *Business Combinations*, and Sections 1601 and 1602 to together replace Handbook Section 1600, *Consolidated Financial Statements*. The adoption of Section 1582 and collectively Sections 1601 and 1602 provides the Canadian equivalent to IFRS 3, *Business Combinations*, and International Accounting Standards (“IAS”) 27, *Consolidated and Separate Financial Statements*, respectively. CICA 1582 applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after January 1, 2011. Section 1601 and Section 1602 apply to interim and annual financial statements relating to years beginning on or after January 1, 2011.

The impact of these standards, effective for the Company on January 1, 2011, on the Company’s financial statements has not been determined.

International Financial Reporting Standards

In February 2008, the CICA confirmed that the use of IFRS will be required, for fiscal years beginning on or after January 1, 2011, for publically accountable profit-oriented enterprises. After that date, IFRS will replace Canadian GAAP for those enterprises. The Company has conducted a preliminary assessment of the impact of these new accounting standards on its consolidated financial statements. A detailed assessment will be conducted in 2010. Changes in accounting policies are likely and may materially impact the Company’s financial statements.

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

3 Projects under development

The Company's projects relate to the repositioning of drugs with a previous clinical history for new or expanded disease indications, with a focus on ophthalmology. The primary activities associated with these projects include the planning and running of human clinical trial programs, regulatory submission preparation, and pre-clinical studies. The Company currently has three projects: iCo-007, an anti-sense compound currently in a Phase I clinical trial for the treatment of diabetic macular edema; iCo-008, a monoclonal antibody that is in the preparation stage for a Phase II clinical trial in allergic conjunctivitis; and iCo-009, an oral formulation of Amphotericin B for the treatment of systemic fungal infections that is at the pre-clinical stage.

Cumulative research and development expenses as at December 31, 2009 relating to these projects totalled \$5,883,556 (2008 - \$5,333,662) (note 10). As at December 31, 2009, the Company has not deferred any development costs due to the inherent uncertainty of these products reaching successful commercialization.

4 Equipment

	2009		
	Cost	Accumulated amortization	Net
	\$	\$	\$
Computer equipment	31,993	24,304	7,689
Computer software	14,258	7,279	6,979
Office equipment	4,989	3,143	1,846
	51,240	34,726	16,514
	2008		
	Cost	Accumulated amortization	Net
	\$	\$	\$
Computer equipment	35,934	18,034	17,900
Computer software	7,254	4,168	3,086
Office equipment	4,989	2,145	2,844
	48,177	24,347	23,830

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

5 Intangible assets

	2009	2008
	\$	\$
Cost		
ISIS (iCo-007)	599,071	599,071
Medimmune (iCo-008)	464,935	464,935
	<hr/>	<hr/>
	1,064,006	1,064,006
Accumulated amortization	405,467	299,001
	<hr/>	<hr/>
Net book value	658,539	765,005
	<hr/>	<hr/>

- a) The Company entered into a licensing agreement with Isis Pharmaceuticals Inc. (“ISIS”) dated August 24, 2005 (amended September 4, 2007), pursuant to which the Company was granted an exclusive, worldwide license to use certain patented technology (iCo-007) in consideration for a license issuance fee of \$599,071 (US\$500,000), which was capitalized as an intangible asset.

The Company will also pay a royalty based on future sales. In accordance with the license agreement, the Company issued a note payable for \$287,365 (US\$250,000) and paid cash of \$308,321. On April 26, 2006, the note payable for US\$250,000 was converted into 362,094 common shares at \$0.80 per share.

During the year ended December 31, 2007, the Company made a payment of \$234,920 (US\$200,000) and issued 936,875 units comprising one common share and one-quarter of one common share purchase warrant at \$1.40 each totalling \$1,311,625 (US\$1,250,000) in consideration for the attainment of two milestones, being the filing of an investigational new drug (“IND”) application and the execution of a clinical site agreement. These milestone payments have been expensed as research and development costs. In addition to the milestone payment described above, the Company will make further payments of up to US\$22 million upon the attainment of certain milestones relating to the commercial development of the iCo-007 for diabetic macular edema.

No milestone payments were made in 2009 as no milestones were reached during the year.

- b) On December 20, 2006 (amended December 4, 2007), the Company entered into a license agreement with Medimmune Limited (“Medimmune”) to acquire the exclusive, worldwide rights to a drug compound (iCo-008) to be developed by the Company primarily for sight threatening forms of allergic conjunctivitis. In exchange, the Company will pay an initial consideration of \$464,935 (US\$400,000), of which \$173,610 (US\$150,000) was paid in December 2006. An additional \$291,325 (US\$250,000) was accrued at December 31, 2006 for the balance of initial consideration, of which \$151,605 (US\$150,000) was paid in December 31, 2007 and the balance of \$113,638 (US\$100,000) plus accrued interest of \$1,349 (US\$1,542) was paid on June 17, 2008. Additional payments of up to US\$7 million will be made upon achieving certain development milestones; however, no milestones have been reached as at December 31, 2009. A royalty will also be paid based on future sales.

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

6 Capital stock

Authorized
Unlimited number of common shares

Issued and outstanding

	Number of shares	Amount \$
Balance - December 31, 2007	17,913,181	9,562,359
Issuance of common shares for cash (d)	3,801,500	1,140,450
Share issuance costs	-	(58,154)
Exercise of options	25,000	3,750
Exercise of warrants	15,269	4,276
Transfer from contributed surplus on exercise of options	-	3,218
Transfer from warrants on exercise of warrants	-	11,022
Balance - December 31, 2008	21,754,950	10,666,921
Issuance of common shares for cash (c)	6,462,500	994,231
Share issuance costs (c)	-	(42,351)
Issuance of common shares for cash (b)	1,187,500	475,000
Share issuance costs (b)	-	(22,750)
Options exercised	19,643	5,500
Warrants exercised	527,500	158,250
Issuance of shares for cash (a)	8,333,333	3,889,920
Share issuance costs (a)	-	(440,035)
Transfer from contributed surplus on exercise of options	-	589
Transfer from warrants on exercise of warrants	-	48,692
Balance - December 31, 2009	38,285,426	15,733,967

- a) The Company closed a private placement in two tranches, with 6,000,000 common shares issued on October 29, 2009 and an additional 2,333,333 common shares issued on November 20, 2009. The shares were issued at a price of \$0.48 per share, for aggregate gross proceeds of \$4,000,000. Of the gross proceeds, \$110,080 was attributable to compensation options (the "Compensation Options"). 333,334 Compensation Options are treated the same as warrants and were granted to Agents along with an aggregate cash commission of 8% totalling \$230,400. Each Compensation Option is exercisable for one common share at an exercise price of \$0.60 for a period of 12 months from the date of issuance. The issuance costs, including the 8% commission, totalled \$452,487 of which \$12,452 was allocated to warrants. The assumptions used to estimate the fair value of warrants issued were: dividend yield 0%; volatility 181%; expected life 12 months; and risk-free interest rate 0.58%.

iCo Therapeutics Inc.

(a development stage company)

Notes to Financial Statements

December 31, 2009 and 2008

- b) On July 16, 2009 the Company closed on a private placement common share offering (the “Offering”) for total gross proceeds of \$475,000. The issuance costs totalled \$22,750. Under the Offering, the Company issued 1,187,500 common shares at a price of \$0.40 per common share.
- c) At February 9, 2009, the Company completed a private placement for gross proceeds of \$1,292,500 through the issuance of 6,462,500 units at a price of \$0.20 per unit. Each unit comprised one common share and one-half of one common share purchase warrant. Each warrant is exercisable at \$0.30 for a period of 12 months. Of the gross proceeds, \$298,269 was attributable to warrants. In addition, issuance costs of \$54,428 were incurred of which \$42,351 was allocated to share capital and \$12,077 was allocated to warrants. The assumptions used to estimate the fair value of warrants issued were: dividend yield 0%; volatility 195%; expected life 12 months; and risk-free interest rate 0.82%.
- d) On June 6 and June 9, 2008, the Company completed a private placement for gross proceeds of \$1,140,450 through the issuance of 3,801,500 units at a price of \$0.30 per unit.

Escrow shares

At December 31, 2009, 2,146,411 (2008 - 3,577,351) common shares (including common shares held by certain officers, directors and insiders of the Company) were held in escrow pursuant to National Policy 46-201, Escrow for Initial Public Offerings. On January 7, 2009 and July 7, 2009, 715,470 and 715,470 common shares, respectively, were released from escrow. The remaining shares in escrow will be released at 15% increments (715,470 common shares) every six months until January 2011.

Stock options

Under the stock option plan (the “2007 Option Plan”) dated December 31, 2007 (the “Effective Date”) whereby up to 2,686,977 common shares representing 7% of the issued and outstanding common shares as at the Effective Date are reserved for issuance pursuant to the exercise of stock options. On April 30, 2009, the 2007 Option Plan was amended to increase the aggregate number of common shares reserved for issuance to 3,200,000.

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

	Number of stock options outstanding	Weighted average exercise price \$
Balance - December 31, 2007	1,531,072	0.42
Granted	260,000	0.87
Exercised	(25,000)	0.15
Balance - December 31, 2008	1,766,072	0.52
Granted	925,000	0.50
Exercised	(19,643)	0.28
Forfeited	(150,000)	0.98
Balance - December 31, 2009	<u>2,521,429</u>	<u>0.49</u>

Of the total stock options outstanding, 1,856,847 (2008 - 1,539,749) were exercisable at year-end.

The following table summarizes information about common share options outstanding and exercisable at December 31, 2009:

Range of exercise price \$	Options outstanding			Options exercisable	
	Number Outstanding at December 31, 2009	Weighted average remaining contractual life (years)	Weighted average exercise price \$	Number exercisable at December 31, 2009	Weighted average exercise price \$
0.15 - 0.28	921,429	1.18	0.18	888,095	0.18
0.40 - 0.60	900,000	4.58	0.55	283,333	0.56
0.80 - 0.80	610,000	1.41	0.80	610,000	0.80
0.98 - 1.00	90,000	2.31	0.99	75,419	0.99
	<u>2,521,429</u>	<u>2.49</u>	<u>0.49</u>	<u>1,856,847</u>	<u>0.47</u>

For the year ended December 31, 2009, the Company recognized \$150,676 (2008 - \$132,021) in stock-based compensation for options granted to directors, officers and employees, and recognized \$38,970 (2008 - \$47,947) in stock-based compensation for stock options granted to non-employees.

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

The fair value of each option granted is estimated as at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

	2009	2008
Dividend yield	0%	0%
Expected volatility	82% - 190%	119%
Risk-free interest rate	0.34% - 2.42%	4.00%
Expected life (years)	1 - 5	2 - 5

Warrants

	Number of warrants	Transfer to capital stock on exercise of warrants \$	Amount \$
Balance - December 31, 2007	2,886,264		788,269
Transfer to capital stock on exercise of warrants	(15,269)		(11,022)
Expired warrants	<u>(2,870,995)</u>		<u>(777,247)</u>
Balance - December 31, 2008	-		-
Private placement (c)	3,231,250	0.30	298,269
Warrant issue costs (c)	-		(12,077)
Private placement (a)	333,334	0.60	110,080
Warrant issue costs (a)	-		(12,452)
Transfer to capital stock on exercise of warrants	<u>(527,500)</u>	0.30	<u>(48,692)</u>
Balance - December 31, 2009	<u>3,037,084</u>		<u>335,128</u>

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

Contributed surplus

	\$
Balance - December 31, 2007	456,615
Stock-based compensation	179,968
Transfer to capital stock on exercise of options	(3,218)
Expiration of warrants	<u>777,247</u>
Balance - December 31, 2008	1,410,612
Stock-based compensation	189,646
Transfer to capital stock on exercise of options	<u>(589)</u>
Balance - December 31, 2009	<u>1,599,669</u>

7 Income taxes

The Company has the following non-capital losses available to reduce taxable income of future years:

Expiry date	\$
2015	337,073
2026	1,844,870
2027	3,254,319
2028	2,782,923
2029	2,392,171

Future tax assets comprise the following:

	2009 \$	2008 \$
Non-capital losses carried forward	2,652,839	2,491,984
SR&ED expenditures	253,394	127,760
Equipment	444,056	90,416
Share issue costs	<u>122,846</u>	<u>209,819</u>
	3,473,135	2,919,979
Valuation allowance	<u>(3,473,135)</u>	<u>(2,919,979)</u>
Net future tax assets	<u>-</u>	<u>-</u>

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

Management believes there is sufficient uncertainty regarding the realization of future tax assets such that a full valuation allowance has been provided.

The Company's effective income tax rate differs from the statutory income tax rate. The differences arise from the following items:

	2009	2008
	\$	\$
Income tax at statutory rate	(579,188)	(713,016)
Change in valuation allowance	410,417	576,997
Change in future tax rate	96,062	86,217
Permanent differences	58,736	49,802
Other	13,973	-
	<hr/>	<hr/>
	-	-
	<hr/>	<hr/>

8 Related party transactions

During the year ended December 31, 2009:

- a) the Company incurred consulting fees totalling \$nil (2008 - \$25,000). The amounts outstanding as at December 31, 2009 totalled \$nil (2008 - \$18,750). All transactions were recorded at their exchange amounts. The amounts bear no interest and are unsecured with no terms of repayment.
- b) the Company incurred director's fees totalling \$3,000 (2008 - \$21,000). The amounts outstanding as at December 31, 2009 totalled \$nil (2008 - \$9,000). All transactions were recorded at their exchange amounts. The amounts bear no interest and are unsecured with no terms of repayment.
- c) directors and officers of the Company subscribed for shares as part of private placements. 458,250 (2008 - 190,000) units of the Company were issued to these directors, officers and related parties for gross proceeds of \$115,110 (2008 - \$57,000 in the June 6 and June 9, 2008 private placements) (note 6(a), (b), (c) and (d)). 2,150,000 units of the Company were also issued to Isis Pharmaceuticals, Inc., a shareholder holding greater than 10% of the Company, for gross proceeds of \$430,000.
- d) 690,000 options were granted to directors and officers of the Company (2008 - no options) to purchase common shares of the Company. Of these options, 100,000 options were granted on February 18, 2009 and have a strike price of \$0.18. The remaining 590,000 options have a strike price of \$0.54 and were granted on December 29, 2009.

iCo Therapeutics Inc.

(a development stage company)

Notes to Financial Statements

December 31, 2009 and 2008

9 Segmented information

The Company identifies its operating segments based on business activities, management responsibility and geographical location. The Company operates within a single operating segment, being the research and development of ophthalmic indications, and operates in one geographic area, being Canada. All of the Company's assets are located in Canada.

10 Research and development

	Year ended December 31, 2009 \$	Year ended December 31, 2008 \$	Cumulative from inception to December 31, 2009 \$
Personnel	191,207	391,274	1,207,419
Research projects	549,894	751,472	5,883,556
Intellectual property	127,225	148,989	570,291
Business development	133,848	87,130	463,375
Travel	57,249	79,193	349,169
Facilities	74,273	79,379	336,989
	<hr/>	<hr/>	<hr/>
	1,133,696	1,537,437	8,810,799
Government assistance (IRAP contribution) (a)	-	(65,796)	(96,389)
Investment tax credits	-	(50,383)	(468,407)
	<hr/>	<hr/>	<hr/>
	1,133,696	1,421,258	8,246,003

- a) On October 11, 2007, the Company entered into a funding contribution agreement with the National Research Council Canada ("NRC") for up to \$98,010 from the Industrial Research Assistance Program ("IRAP"). The NRC had committed this money to the Company to support its development of an oral Amphotericin B formulation for the treatment of fungal disease. If the NRC determines that certain objectives under the contribution agreement cannot be realized, the Company may be liable to repay contributions received. Under this IRAP program, the Company claimed contributions in the December 31, 2009 year totalling \$nil (2008 - \$65,796). Contributions are recorded as a credit to research and development expense. The IRAP program ended in October 2008, and there are no liabilities related to the NRC.

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

11 General and administrative

	Year ended December 31, 2009	Year ended December 31, 2008	Cumulative from inception to December 31, 2009
	\$	\$	\$
Personnel	354,375	455,242	1,401,178
Professional fees	378,432	419,749	1,646,016
Travel	68,060	71,524	350,694
Facilities	36,080	48,782	202,758
	<u>836,947</u>	<u>995,297</u>	<u>3,600,646</u>

12 Commitments and contingencies

a) Lease commitments

In January 2009, the Company extended its operating lease agreement for office space (originally expiring May 31, 2009). The new lease expires May 31, 2012. Future minimum annual lease payments under the lease are as follows:

	\$
2010	27,195
2011	28,455
2012	12,075

Rent expense for the year ended December 31, 2009 amounted to \$46,595 (2008 - \$42,920).

b) Contractual commitments

The Company may be required to make milestone, royalty, and other research and development funding payments under research and development collaboration and other agreements with third parties. These payments are contingent upon the achievement of specific development, regulatory and/or commercial milestones. The Company has not accrued for these payments as of December 31, 2009 due to the uncertainty over whether these milestones will be achieved. The Company's significant contingent milestone, royalty and other research and development commitments are as follows:

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

ISIS

In connection with the licensing agreement between ISIS and the Company, the Company may be required to make additional contingent payments of up to US\$22 million upon the achievement of certain development and commercialization milestones of iCo-007 in its first ocular indication (note 5(a)). In addition, the Company may be required to pay royalties on future revenues. The Company may also be required to make additional contingent payments upon the achievement of certain development and commercialization milestones of iCo-007 in other ocular and non-ocular disease indications.

Medimmune

In connection with its licence agreement between Medimmune and the Company, the Company was required to make up-front payments totalling US\$400,000, of which the last payment was made in December, 2007. The Company may be required to make additional contingent payments of up to US\$7 million upon the achievement of certain development and commercialization milestones (note 5(b)). In addition, the Company may be required to pay royalties on future revenues. The Company may also be required to make additional contingent payments upon the achievement of certain development and commercialization milestones for products developed outside the ocular field.

University of British Columbia (“UBC”)

On May 6, 2008, the Company signed an agreement with UBC for the exclusive worldwide licence to iCo-009 (the “UBC Licence”). In consideration for the UBC Licence, the Company paid UBC an initial licence fee of \$20,000 and is required to pay annual fees to UBC for maintaining the licence until such time as a New Drug Application (“NDA”) for iCo-009 is approved. The Company is required to make additional contingent payments of up to \$1,900,000 in aggregate upon the achievement of certain development and commercialization milestones and is also required to pay royalties on future revenues. The UBC Licence additionally obligated the Company to contribute research funding (which may be in the form of direct payments from the Company or indirect payments, such as securing research grants) to UBC for the iCo-009 program.

In February 2009, the Company was successful in securing research funding for iCo-009 through the award of a Canadian Institute of Health Research (“CIHR”) Research Chair (the “Research Chair”) to fund research over a four-year period. Under the budget program established by the Research Chair, the Company is required to directly contribute \$75,000 per annum starting in fiscal 2009 and ending in fiscal 2012. In consideration of securing the Research Chair, on February 23, 2009 UBC provided notification to the Company that its obligation to UBC under the UBC Licence to secure the research funding for iCo-009 would be satisfied in its entirety as long as the Company met its funding obligations under the Research Chair and fulfilled its obligation to pay UBC an additional \$90,000 in direct research funding previously committed to by the Company for 2009. The Company has met all its financial obligations to UBC and the Research Chair for 2009.

iCo Therapeutics Inc.

(a development stage company)

Notes to Financial Statements

December 31, 2009 and 2008

In September, 2009, the Company also entered into a collaboration development agreement with the Consortium for Parasitic Drug Development (“CPDD”) for up to US\$182,930 for the research and development of the Company’s oral drug delivery technology for the treatment of neglected diseases such as leishmaniasis and trypanosomiasis.

13 Financial Instruments

Fair Value

Amendments to CICA Handbook Section 3862, *Financial Instruments - Disclosures*, establish a fair value hierarchy that requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company primarily applies the market approach for recurring fair value measurements. The section describes three input levels that may be used to measure fair value:

Level 1 - unadjusted quoted prices in active markets for identical assets or liabilities. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide information on an ongoing basis.

Level 2 - quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Financial instruments whose carrying value approximates fair value

Cash and cash equivalents, and accounts payable and accrued liabilities are financial instruments whose fair value approximates their carrying value due to their short-term maturity. The input level used by the Company to measure fair value of its cash and cash equivalents is a Level 2 input as they are valued using observable market data.

Foreign exchange risk

Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

iCo Therapeutics Inc.
(a development stage company)
Notes to Financial Statements
December 31, 2009 and 2008

Balances in foreign currencies at December 31, 2009 and 2008 are as follows:

	2009	2008
	US balance	US balance
	\$	\$
Cash and cash equivalents	37,785	34,158
Accounts payable	(162,516)	(195,142)
	<u>(124,731)</u>	<u>(160,984)</u>

Based on the US dollar balance sheet exposure at December 31, 2009, with other variables unchanged, a 10% change in the US dollar compared to the US dollar would not have a significant impact on and the statement of operations, comprehensive loss and deficit.

Interest rate risk

The only financial instruments that expose the Company to interest rate risk are its cash and cash equivalents and short term investments. Cash and cash equivalents in excess of day-to-day requirements are placed in short-term deposits with high quality credit financial institutions and earn interest at rates available at that time.

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in raising funds to meet cash flow requirements associated with financial instruments. The recent problems in the global credit markets have resulted in a drastic reduction in the ability of companies to raise capital through the public markets.

In January and February of 2010, the remaining warrants were exercised for gross proceeds of \$810,563 (note 15). Also see note 1 - going concern, for additional comments relating to liquidity risk.

The Company continues to manage its liquidity risk by being fairly consistent with outflows experienced for the year ended December 31, 2009 and is undertaking efforts to conserve cash resources wherever possible.

iCo Therapeutics Inc.

(a development stage company)

Notes to Financial Statements

December 31, 2009 and 2008

Credit risk

The Company's exposure to credit risk consists of the carrying value of its cash and cash equivalents.

The Company limits its exposure to credit risk, with respect to cash and cash equivalents, by placing them with high quality credit financial institutions. The Company's cash equivalents consist primarily of operating funds and deposit investments with commercial banks. Of the amounts with financial institutions on deposit, the following table summarizes the amounts at risk should the financial institutions with which the deposits are held cease trading:

	Cash and cash equivalents \$	Insured amount \$	Non-insured amount \$
CIBC	1,904,507	100,000	1,804,507
Government of Canada	1,001,569	1,001,569	-
Raymond James	508,871	508,871	-
Manulife	481,118	481,118	-
	<u>3,896,065</u>	<u>2,091,558</u>	<u>1,804,507</u>

14 Capital management

The Company considers its capital stock and contributed surplus as capital. As at December 31, 2009, the amount of capital totalled \$17,333,636 (2008 - \$12,077,533).

The Company manages its capital structure in order to ensure sufficient resources are available to meet day-to-day operation requirements, further develop its existing technology, and advance its clinical trials.

The Company manages its capital through quarterly board of director meetings and regular review of financial information.

The Company is not subject to any externally exposed capital requirements.

15 Subsequent events

In January and February 2010, 2,701,875 outstanding warrants (the "Warrants") were exercised for total gross proceeds of \$810,563. The Warrants were issued pursuant to a private placement completed by the Company which closed in two tranches on January 30, 2009 and February 9, 2009, respectively. The Warrants were exercisable at \$0.30 for a period of twelve months from closing of the private placement.